Base de dados : MEDLINE
Pesquisa : D08.811.277.450.529 [Categoria DeCS]
Referências encontradas : 5477 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 548 ir para página                         

  1 / 5477 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28467350
[Au] Autor:Santos HFD; Campos JF; Santos CMD; Balestieri JBP; Silva DB; Carollo CA; de Picoli Souza K; Estevinho LM; Dos Santos EL
[Ad] Endereço:Research group on Biotechnology and Bioprospecting Applied to Metabolism (GEBBAM), Federal University of Grande Dourados, Rodovia Dourados Itahum, Km 12, 79804-970 Dourados, MS, Brazil. helderspk@gmail.com.
[Ti] Título:Chemical Profile and Antioxidant, Anti-Inflammatory, Antimutagenic and Antimicrobial Activities of Geopropolis from the Stingless Bee Melipona orbignyi.
[So] Source:Int J Mol Sci;18(5), 2017 May 03.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Geopropolis is a resin mixed with mud, produced only by stingless bees. Despite being popularly known for its medicinal properties, few scientific studies have proven its biological activities. In this context, the objective of this study was to determine the chemical composition and antioxidant, anti-inflammatory, antimutagenic and antimicrobial activities of the geopropolis. The hydroalcoholic extract of geopropolis (HEGP) was prepared and its chemical composition determined by high performance liquid chromatography coupled to diode array detector and mass spectrometry (HPLC-DAD-MS). The antioxidant activity was determined by the capture of free radicals and inhibition of lipid peroxidation in human erythrocytes. The anti-inflammatory activity was evaluated by the inhibition of the hyaluronidase enzyme and the antimutagenic action was investigated in colonies. The antimicrobial activities were determined against bacteria and yeasts, isolated from reference strains and hospital origin. The chemical composition of HEGP included flavonoids, derivatives of glycosylated phenolic acids and terpenoids. HEGP showed high antioxidant activity, it inhibited the activity of the inflammatory enzyme hyaluronidase and reduced the mutagenic effects in . In relation to the antimicrobial activity, it promoted the death of all microorganisms evaluated. In conclusion, this study reveals for the first time the chemical composition of the HEGP of and demonstrates its pharmacological properties.
[Mh] Termos MeSH primário: Anti-Infecciosos
Anti-Inflamatórios
Antioxidantes
Abelhas/química
Própole
[Mh] Termos MeSH secundário: Animais
Anti-Infecciosos/química
Anti-Infecciosos/farmacologia
Anti-Inflamatórios/química
Anti-Inflamatórios/farmacologia
Antioxidantes/química
Antioxidantes/farmacologia
Bactérias/efeitos dos fármacos
Cromatografia Líquida de Alta Pressão
Eritrócitos/efeitos dos fármacos
Metanossulfonato de Etila/farmacologia
Flavonoides/análise
Radicais Livres/análise
Seres Humanos
Hialuronoglucosaminidase/efeitos dos fármacos
Hidroxibenzoatos/análise
Peroxidação de Lipídeos/efeitos dos fármacos
Espectrometria de Massas
Mutagênicos
Própole/química
Própole/farmacologia
Saccharomyces cerevisiae/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Flavonoids); 0 (Free Radicals); 0 (Hydroxybenzoates); 0 (Mutagens); 29656-58-4 (phenolic acid); 9009-62-5 (Propolis); 9H154DI0UP (Ethyl Methanesulfonate); EC 3.2.1.35 (Hyaluronoglucosaminidase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE


  2 / 5477 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458347
[Au] Autor:Panthavee W; Noda M; Danshiitsoodol N; Kumagai T; Sugiyama M
[Ad] Endereço:Department of Probiotic Science for Preventive Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University.
[Ti] Título:Characterization of Exopolysaccharides Produced by Thermophilic Lactic Acid Bacteria Isolated from Tropical Fruits of Thailand.
[So] Source:Biol Pharm Bull;40(5):621-629, 2017.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:In the present study, we have obtained two exopolysaccharide (EPS)-producing thermophilic lactic acid bacteria (LAB) that were isolated from tropical fruits of Thailand. The two strains, designated LY45 and PY45, were identified as Pediococcus pentosaceus and Lactobacillus amylovorus, respectively. Both plant-derived LAB strains, which produce neutral EPSs together with the acidic one, can grow vigorously at 45°C and even at 50°C. Hyaluronidase (EC 3.2.1.35), which catalyzes the degradation of hyaluronic acid, activates an inflammatory reaction. Interestingly, EPSs produced by the LY45 and PY45 strains were found to inhibit hyaluronidase activity at the same order of IC values as did sodium cromoglicate and dipotassium glycyrrhizinate, which are well-known as anti-inflammatory agents. The LY45-derived neutral EPS consists of glucose and mannose as monosaccharide components, whereas the acidic one contains mainly mannose, together with glucose and galactose. On the other hand, although Lactobacillus amylovorus PY45 also produces neutral and acidic EPSs, the main monosaccharide in both EPSs is mannose, and glucose is a minor component. Furthermore, the PY45 strain may be probiotically and industrially useful because the microorganism can utilize starch and glycogen as carbon sources.
[Mh] Termos MeSH primário: Frutas/microbiologia
Lactobacillus/química
Pediococcus/química
Polissacarídeos/química
Polissacarídeos/farmacologia
[Mh] Termos MeSH secundário: Meios de Cultura
DNA Bacteriano/genética
Fermentação
Galactose/química
Glucose/química
Hialuronoglucosaminidase/antagonistas & inibidores
Ácido Láctico/metabolismo
Lactobacillus/genética
Manose/química
Pediococcus/genética
Açúcares/análise
Temperatura Ambiente
Tailândia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Culture Media); 0 (DNA, Bacterial); 0 (Polysaccharides); 0 (Sugars); 33X04XA5AT (Lactic Acid); EC 3.2.1.35 (Hyaluronoglucosaminidase); IY9XDZ35W2 (Glucose); PHA4727WTP (Mannose); X2RN3Q8DNE (Galactose)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b16-00856


  3 / 5477 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29210299
[Au] Autor:Czarnecka K; Girek M; Maciejewska K; Skibinski R; Jonczyk J; Bajda M; Kabzinski J; Solowiej P; Majsterek I; Szymanski P
[Ad] Endereço:a Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy , Medical University of Lodz , Lodz , Poland.
[Ti] Título:New cyclopentaquinoline hybrids with multifunctional capacities for the treatment of Alzheimer's disease.
[So] Source:J Enzyme Inhib Med Chem;33(1):158-170, 2017 Dec.
[Is] ISSN:1475-6374
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Alzheimer's disease (AD) is the most common progressive form of brain neurodegeneration and the most prevailing cause of dementia. Unfortunately, the aetiology of AD is not completely studied but different factors are associated with the development of AD such as among others low level of acetylcholine, aggregation of ß-amyloid (Aß), hyperphosphorylated tau protein, oxidative stress, and inflammation. The study encompass organic syntheses of 2,3-dihydro-1H-cyclopenta[b]quinoline with 5,6-dichloronicotinic acid and suitable linkers derivatives as multifunctional agents for AD treatment. Afterwards self-induced amyloid beta aggregation, inhibition studies of acetylcholinesterase and butyrylcholinesterase and molecular docking studies were performed. The results showed that 3b compound exhibited the best acetylcholinesterase inhibitory activity, with IC value of 0.052 µM which is lower compared to references. Besides, all synthesised compounds showed good butyrylcholinesterase inhibitory activity with IC values from 0.071 to 0.797 µM. Compound 3b exhibited strong Aß aggregation inhibitory effect with 25.7% at 5 µM to 92.8% at 100 µM as well as good anti-inflammatory effect. Thus, new compounds could create new perspectives for further development as a multi-target-directed agent for AD treatment.
[Mh] Termos MeSH primário: Acetilcolinesterase/metabolismo
Doença de Alzheimer/tratamento farmacológico
Aminoquinolinas/farmacologia
Butirilcolinesterase/metabolismo
Inibidores da Colinesterase/farmacologia
Inibidores de Glicosídeo Hidrolases/farmacologia
Hialuronoglucosaminidase/antagonistas & inibidores
Niacinamida/análogos & derivados
[Mh] Termos MeSH secundário: Doença de Alzheimer/metabolismo
Aminoquinolinas/síntese química
Aminoquinolinas/química
Peptídeos beta-Amiloides/antagonistas & inibidores
Peptídeos beta-Amiloides/metabolismo
Animais
Proliferação Celular/efeitos dos fármacos
Inibidores da Colinesterase/síntese química
Inibidores da Colinesterase/química
Relação Dose-Resposta a Droga
Enguias
Inibidores de Glicosídeo Hidrolases/síntese química
Inibidores de Glicosídeo Hidrolases/química
Cavalos
Seres Humanos
Hialuronoglucosaminidase/metabolismo
Modelos Moleculares
Estrutura Molecular
Niacinamida/síntese química
Niacinamida/química
Niacinamida/farmacologia
Fragmentos de Peptídeos/antagonistas & inibidores
Fragmentos de Peptídeos/metabolismo
Agregados Proteicos/efeitos dos fármacos
Relação Estrutura-Atividade
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (5,6-dichloro-N-(3-(2,3-dihydro-1H-cyclopenta(b)quinolin-9-ylamino)propyl)nicotinamide); 0 (Aminoquinolines); 0 (Amyloid beta-Peptides); 0 (Cholinesterase Inhibitors); 0 (Glycoside Hydrolase Inhibitors); 0 (Peptide Fragments); 0 (Protein Aggregates); 0 (amyloid beta-protein (1-42)); 25X51I8RD4 (Niacinamide); EC 3.1.1.7 (Acetylcholinesterase); EC 3.1.1.8 (Butyrylcholinesterase); EC 3.2.1.35 (Hyaluronoglucosaminidase)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE
[do] DOI:10.1080/14756366.2017.1406485


  4 / 5477 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28858168
[Au] Autor:Harrison J; Rhodes O
[Ad] Endereço:Jeanine Harrison, BScN, MN, RN-EC, NP, is Nurse Practitioner, TH Medical Aesthetics, Thornhill, Ontario, Canada. Oriol Rhodes RN, BAS, MBA, is Registered Nurse, TH Medical Aesthetics, Thornhill, Ontario, Canada.
[Ti] Título:Hyaluronidase: Understanding Its Properties and Clinical Application for Cosmetic Injection Adverse Events.
[So] Source:Plast Surg Nurs;37(3):109-111, 2017 Jul/Sep.
[Is] ISSN:1550-1841
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The recent global consensus on the management of cosmetic aesthetic injectable complications from hyaluronic acid (HA) has increased the focus on the use of hyaluronidase more than ever before (M. Signorini et al., 2016). A comprehensive knowledge of facial anatomy, including structural positioning of facial arteries and veins, and an extensive knowledge of HA products available for injection procedures, combined with best practice protocols, will assist to prevent adverse events. Despite the growing number of patients using cosmetic fillers for facial restoration, the incidents incidence of adverse events remains low. Indeed, the avoidance of complications through safe and effective injection practice remains the key to preventing the need to use hyaluronidase.
[Mh] Termos MeSH primário: Técnicas Cosméticas/efeitos adversos
Preenchedores Dérmicos/efeitos adversos
Hialuronoglucosaminidase/farmacologia
[Mh] Termos MeSH secundário: Contraindicações
Relação Dose-Resposta a Droga
Composição de Medicamentos
Face
Seres Humanos
Ácido Hialurônico/química
Hialuronoglucosaminidase/efeitos adversos
Injeções/efeitos adversos
Injeções/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dermal Fillers); 9004-61-9 (Hyaluronic Acid); EC 3.2.1.35 (Hyaluronoglucosaminidase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE
[do] DOI:10.1097/PSN.0000000000000193


  5 / 5477 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28724193
[Au] Autor:Gopalakrishnan PN; Goel N; Banerjee S
[Ad] Endereço:Department of Neonatology, Wishaw General Hospital, 50 Netherton St, Wishaw, Lanarkshire, Scotland, UK, ML2 0DP.
[Ti] Título:Saline irrigation for the management of skin extravasation injury in neonates.
[So] Source:Cochrane Database Syst Rev;7:CD008404, 2017 07 19.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Extravasation injury, a complication commonly seen in the neonatal intensive care unit, can result in scarring with cosmetic and functional sequelae. A wide variety of treatments are available, including subcutaneous irrigation with saline (with or without hyaluronidase), liposuction, use of specific antidotes, topical applications, and normal wound care with dry or wet dressings. All such treatments aim to prevent or reduce the severity of complications. OBJECTIVES: Primary objective To compare the efficacy and safety of saline irrigation or saline irrigation with prior hyaluronidase infiltration versus no intervention or normal wound care for tissue healing in neonates with extravasation injury. Secondary objectives To evaluate by subgroup analysis of controlled trials the influence of type of extravasate, timing of irrigation following extravasation, and postmenstrual age (PMA) of the neonate at the time of injury on outcomes and adverse effects.Specifically, we planned to perform subgroup analysis for the primary outcome, if appropriate, by examining:1. time to irrigation from identified extravasation injury (< 1 hour or ≥ 1 hour);2. type of extravasate (parenteral nutrition fluid or other fluids or medications);3. amount of saline used (< 500 mL or ≥ 500 mL); and4. PMA at injury (< 37 completed weeks or ≥ 37 completed weeks). SEARCH METHODS: We used the standard search strategy of the Cochrane Neonatal Review Group to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1), MEDLINE via PubMed (1966 to 2 February 2017), Embase (1980 to 2 February 2017), and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to 2 February 2017). We also searched clinical trial databases, conference proceedings, and reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. We used the Google Scholar search tool for reverse citations of relevant articles. SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-randomised controlled trials comparing saline irrigation with or without hyaluronidase infiltration versus no intervention or normal wound care for the management of extravasation injury in neonates. DATA COLLECTION AND ANALYSIS: Three review authors independently reviewed and identified articles for possible inclusion in this review. We used the GRADE approach to assess the quality of evidence. MAIN RESULTS: We found no eligible studies. Our search revealed 10 case reports or case series describing successful outcomes with different interventions for this condition. AUTHORS' CONCLUSIONS: To date, no RCTs have examined the effects of saline irrigation with or without prior hyaluronidase infiltration for management of extravasation injury in neonates. Saline irrigation is frequently reported in the literature as an intervention for management of extravasation injury in neonates. Research should focus first on evaluating the efficacy and safety of this intervention through RCTs. It will also be important for investigators to determine effect size by examining the timing of the intervention, the nature of the infusate, and severity of injury at the time of intervention.
[Mh] Termos MeSH primário: Extravasamento de Materiais Terapêuticos e Diagnósticos/terapia
Hialuronoglucosaminidase/uso terapêutico
Pele/lesões
Cloreto de Sódio/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
Recém-Nascido
Registros Médicos
Soluções
Irrigação Terapêutica/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Solutions); 451W47IQ8X (Sodium Chloride); EC 3.2.1.35 (Hyaluronoglucosaminidase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD008404.pub3


  6 / 5477 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28692601
[Au] Autor:Kao YC; Ranucci V; Zhang L; Sung YS; Athanasian EA; Swanson D; Dickson BC; Antonescu CR
[Ad] Endereço:*Department of Pathology, Memorial Sloan Kettering Cancer Center §Department of Hand and Upper Extremity Surgery, Hospital for Special Surgery, New York, NY †Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan ‡Division of Anatomic Pathology and Histology, Catholic University, Rome, Italy ∥Department of Pathology, Mount Sinai Hospital, Toronto, ON, Canada.
[Ti] Título:Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors.
[So] Source:Am J Surg Pathol;41(11):1456-1465, 2017 Nov.
[Is] ISSN:1532-0979
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Myxoinflammatory fibroblastic sarcoma (MIFS) is a low grade soft tissue sarcoma with a predilection for acral sites, being associated with a high rate of local recurrence but very infrequent distant metastases. Although a t(1;10) translocation resulting in TGFBR3-MGEA5 fusion has been reported as a recurrent genetic event in MIFS, this abnormality is seen only in a subset of cases. As no studies to date have investigated the spectrum of alternative genetic alterations in TGFBR3-MGEA5 fusion negative MIFS, we undertook a genetic analysis of this particular cohort for further molecular classification. Triggered by an index case occurring in the finger of a 37-year-old female and harboring a novel TOM1L2-BRAF fusion by targeted RNA sequencing we investigated potential recurrent BRAF abnormalities by screening a large group of 19 TGFBR3-MGEA5 fusion negative MIFS by fluorescence in situ hybridization. There were 6 (32%) additional MIFS with BRAF genetic abnormalities, including 5 gene rearrangements and one showing BRAF amplification. Interestingly, VGLL3 amplification, a recurrent genetic abnormality coexisting with t(1;10) in some MIFS, was also detected by fluorescence in situ hybridization in 4/6 (67%) BRAF-rearranged MIFS, but not in the BRAF-amplified case. Up-regulated VGLL3 mRNA expression was also demonstrated in the index case by RNA sequencing. The 7 BRAF-rearranged/amplified MIFS arose in the fingers (n=3), and 1 each in wrist, forearm, foot, and knee, of adult patients (36 to 74 y; M:F=4:3). The histologic spectrum ranged from predominantly solid growth of plump histiocytoid to epithelioid tumor cells with focal myxoid change to a predominantly myxoid background with scattered tumor cells. Varying degree of inflammatory infiltrates and large tumor cells with virocyte-like macronucleoli were observed in most cases. Immunohistochemical stains of phosphorylated ERK, a downstream effector of BRAF activation, were positive in all 4 cases tested (2 diffuse strong, 2 focal strong). Unlike t(1;10), BRAF rearrangements were only found in MIFS but not in 6 hemosiderotic fibrolipomatous tumor (HFLT) lacking TGFBR3-MGEA5 fusions (including 2 pure HFLT, 2 hybrid HFLT-MIFS, and 2 associated with pleomorphic hyalinizing angiectatic tumors).
[Mh] Termos MeSH primário: Biomarcadores Tumorais/genética
Fibrossarcoma/genética
Rearranjo Gênico
Hemossiderose/genética
Lipoma/genética
Proteínas Proto-Oncogênicas B-raf/genética
Neoplasias de Tecidos Moles/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Antígenos de Neoplasias/genética
Biomarcadores Tumorais/análise
Proteínas de Transporte/genética
Estudos de Casos e Controles
MAP Quinases Reguladas por Sinal Extracelular/análise
Feminino
Fibrossarcoma/enzimologia
Fibrossarcoma/patologia
Amplificação de Genes
Fusão Gênica
Predisposição Genética para Doença
Hemossiderose/enzimologia
Hemossiderose/patologia
Histona Acetiltransferases/genética
Seres Humanos
Hialuronoglucosaminidase/genética
Imuno-Histoquímica
Hibridização in Situ Fluorescente
Lipoma/enzimologia
Lipoma/patologia
Masculino
Meia-Idade
Gradação de Tumores
Fenótipo
Fosforilação
Proteoglicanas/genética
RNA Mensageiro/genética
Receptores de Fatores de Crescimento Transformadores beta/genética
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Análise de Sequência de RNA
Neoplasias de Tecidos Moles/enzimologia
Neoplasias de Tecidos Moles/patologia
Fatores de Transcrição/genética
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Biomarkers, Tumor); 0 (Carrier Proteins); 0 (Proteoglycans); 0 (RNA, Messenger); 0 (Receptors, Transforming Growth Factor beta); 0 (TOM1L2 protein, human); 0 (Transcription Factors); 0 (VGLL3 protein, human); 145170-29-2 (betaglycan); EC 2.3.1.48 (Histone Acetyltransferases); EC 2.7.11.1 (BRAF protein, human); EC 2.7.11.1 (Proto-Oncogene Proteins B-raf); EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases); EC 3.2.1.169 (MGEA5 protein, human); EC 3.2.1.35 (Hyaluronoglucosaminidase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE
[do] DOI:10.1097/PAS.0000000000000899


  7 / 5477 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28582436
[Au] Autor:Gebauer F; Kemper M; Sauter G; Prehm P; Schumacher U
[Ad] Endereço:Department of General, Visceral and Thoracic Surgery, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
[Ti] Título:Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
[So] Source:PLoS One;12(6):e0178703, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis and the number of PDAC-related deaths is rising. Recently the tumour stroma and in particular one of its main components, hyaluronan (HA), have attracted considerable attention as intravenous hyaluronidase treatment together with conventional chemotherapy considerably prolonged survival in HA-rich PDA patients. We therefore wanted to investigate the prognostic significance of HA deposition in PDA using both antibodies to HA and hyaluronan binding protein (HABP). MATERIAL AND METHODS: Tissue microarrays of PDAs of 184 patients and pancreatic xenografts tumours were immunohistochemically (IHC) stained for HA using either biotinylated hyaluronic acid binding protein (HABP) or anti-HA antibody. RESULTS: The pattern of staining with HABP differed significantly from that with antibody IHC. Antibody staining was found both within cancer cells and in the extracellular matrix and staining could not be eliminated by hyaluronidase predigestion of the tissue sections. In contrast, HABP staining was generally confined to the extracellular matrix and was completely abolished by hyaluronidase pretreatment. HA positivity as determined by HABP was associated with larger primary tumours (p = 0.046). There were no correlations between overall survival, disease-free survival and HA expression. CONCLUSION: Presence of HA alone is not of prognostic importance in PDAC, and IHC with utilization of antibody detection shows no reliable staining pattern and should not be applied for HA IHC.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/metabolismo
Carcinoma Ductal Pancreático/diagnóstico
Regulação Neoplásica da Expressão Gênica
Receptores de Hialuronatos/metabolismo
Ácido Hialurônico/metabolismo
Neoplasias Pancreáticas/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma Ductal Pancreático/genética
Carcinoma Ductal Pancreático/mortalidade
Carcinoma Ductal Pancreático/patologia
Matriz Extracelular/metabolismo
Matriz Extracelular/patologia
Feminino
Seres Humanos
Receptores de Hialuronatos/genética
Hialuronoglucosaminidase/química
Imuno-Histoquímica
Masculino
Meia-Idade
Pâncreas/metabolismo
Pâncreas/patologia
Neoplasias Pancreáticas/genética
Neoplasias Pancreáticas/mortalidade
Neoplasias Pancreáticas/patologia
Prognóstico
Análise de Sobrevida
Análise Serial de Tecidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Hyaluronan Receptors); 9004-61-9 (Hyaluronic Acid); EC 3.2.1.35 (Hyaluronoglucosaminidase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0178703


  8 / 5477 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28498207
[Au] Autor:Juhász MLW; Levin MK; Marmur ES
[Ad] Endereço:*Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; †Marmur Medical, New York, New York; ‡Department of Dermatology, The Mount Sinai Hospital, New York, New York.
[Ti] Título:The Kinetics of Reversible Hyaluronic Acid Filler Injection Treated With Hyaluronidase.
[So] Source:Dermatol Surg;43(6):841-847, 2017 Jun.
[Is] ISSN:1524-4725
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hyaluronidase is an enzyme capable of dissolution of hyaluronic acid (HA). There is a lack of evidence-based research defining time- and concentration-dependent reversal of HA filler using hyaluronidase. OBJECTIVE: To explore the efficacy of different concentrations of hyaluronidase in digesting commercially available HA-based reversible fillers-Belotero Balance (BEL), Juvederm Ultra XC (JUVXC), Juvederm Ultra Plus (JUVX+), Juvederm Voluma XC (JUVV), Restylane-L (RESL), Restylane Silk (RESS), and Perlane/Restylane Lyft (RESLYFT). MATERIALS AND METHODS: This was a blinded randomized study involving 15 participants. Participants received HA filler injection into their back, followed by no secondary injection, or injection with normal saline, 20 or 40 units of hyaluronidase. Using a 5-point palpation scale, the degradation of HA filler was monitored over 14 days. RESULTS: In the authors' study, there is a significant decrease in HA filler degradation using 20 and 40 units of hyaluronidase compared with no secondary injection or normal saline. There is no significant difference in HA filler dissolution when comparing 20 to 40 units of hyaluronidase. CONCLUSION: Lower concentrations of hyaluronidase may be just as effective as higher concentrations to degrade HA filler in situations where the reversal of cutaneous augmentation with HA filler arises.
[Mh] Termos MeSH primário: Preenchedores Dérmicos/farmacocinética
Ácido Hialurônico/farmacocinética
Hialuronoglucosaminidase/farmacologia
[Mh] Termos MeSH secundário: Adulto
Preenchedores Dérmicos/administração & dosagem
Relação Dose-Resposta a Droga
Método Duplo-Cego
Feminino
Seres Humanos
Ácido Hialurônico/administração & dosagem
Injeções Subcutâneas
Masculino
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dermal Fillers); 9004-61-9 (Hyaluronic Acid); EC 3.2.1.35 (Hyaluronoglucosaminidase)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170721
[Lr] Data última revisão:
170721
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170513
[St] Status:MEDLINE
[do] DOI:10.1097/DSS.0000000000001084


  9 / 5477 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28482035
[Au] Autor:Reed MJ; Vernon RB; Damodarasamy M; Chan CK; Wight TN; Bentov I; Banks WA
[Ad] Endereço:Department of Medicine, University of Washington, Seattle.
[Ti] Título:Microvasculature of the Mouse Cerebral Cortex Exhibits Increased Accumulation and Synthesis of Hyaluronan With Aging.
[So] Source:J Gerontol A Biol Sci Med Sci;72(6):740-746, 2017 Jun 01.
[Is] ISSN:1758-535X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The microvasculature of the aged brain is less dense and more vulnerable to dysfunction than that of the young brain. Brain microvasculature is supported by its surrounding extracellular matrix, which is comprised largely of hyaluronan (HA). HA is continually degraded into lower molecular weight forms that induce neuroinflammation. We examined HA associated with microvessels (MV) of the cerebral cortex of young (4 months), middle-aged (14 months), and aged (24-26 months) mice. We confirmed that the density of cortical MV decreased with age. Perivascular HA levels increased with age, but there was no age-associated change in HA molecular weight profile. MV isolated from aged cortex had more HA than MV from young cortex. Examination of mechanisms that might account for elevated HA levels with aging showed increased HA synthase 2 (HAS2) mRNA and protein in aged MV relative to young MV. In contrast, mRNAs for HA-degrading hyaluronidases or hyaladherins that mitigate HA degradation showed no changes with age. Corresponding to increased HAS2, aged MV synthesized significantly more HA (of all molecular weight classes) in vitro than young MV. We propose that increased HA synthesis and accumulation in brain MV contributes to neuroinflammation and reduced MV density and function in aging.
[Mh] Termos MeSH primário: Envelhecimento/metabolismo
Córtex Cerebral/metabolismo
Ácido Hialurônico/biossíntese
Microvasos/metabolismo
[Mh] Termos MeSH secundário: Animais
Córtex Cerebral/irrigação sanguínea
Ensaio de Imunoadsorção Enzimática
Imunofluorescência
Expressão Gênica
Glucuronosiltransferase/genética
Glucuronosiltransferase/metabolismo
Hialuronan Sintases
Hialuronoglucosaminidase/genética
Hialuronoglucosaminidase/metabolismo
Imuno-Histoquímica
Camundongos Endogâmicos C57BL
RNA Mensageiro
Reação em Cadeia da Polimerase em Tempo Real
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (RNA, Messenger); 9004-61-9 (Hyaluronic Acid); EC 2.4.1.17 (Glucuronosyltransferase); EC 2.4.1.212 (Has2 protein, mouse); EC 2.4.1.212 (Hyaluronan Synthases); EC 3.2.1.35 (Hyaluronoglucosaminidase)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170509
[St] Status:MEDLINE
[do] DOI:10.1093/gerona/glw213


  10 / 5477 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28428153
[Au] Autor:Suderman RJ; Rice DA; Gibson SD; Strick EJ; Chao DM
[Ad] Endereço:Nectagen, Inc., 2002 W. 39th Ave, Kansas City, KS 66103, USA. Electronic address: rjs@nectagen.com.
[Ti] Título:Development of polyol-responsive antibody mimetics for single-step protein purification.
[So] Source:Protein Expr Purif;134:114-124, 2017 Jun.
[Is] ISSN:1096-0279
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purification of functional proteins is a critical pre-requisite for many experimental assays. Immunoaffinity chromatography, one of the fastest and most efficient purification procedures available, is often limited by elution conditions that disrupt structure and destroy enzymatic activity. To address this limitation, we developed polyol-responsive antibody mimetics, termed nanoCLAMPs, based on a 16 kDa carbohydrate binding module domain from Clostridium perfringens hyaluronidase. nanoCLAMPs bind targets with nanomolar affinity and high selectivity yet release their targets when exposed to a neutral polyol-containing buffer, a composition others have shown to preserve quaternary structure and enzymatic activity. We screened a phage display library for nanoCLAMPs recognizing several target proteins, produced affinity resins with the resulting nanoCLAMPs, and successfully purified functional target proteins by single-step affinity chromatography and polyol elution. To our knowledge, nanoCLAMPs constitute the first antibody mimetics demonstrated to be polyol-responsive.
[Mh] Termos MeSH primário: Anticorpos
Proteínas de Bactérias
Materiais Biomiméticos/química
Clostridium perfringens/genética
Hialuronoglucosaminidase
Biblioteca de Peptídeos
Polímeros/química
[Mh] Termos MeSH secundário: Proteínas de Bactérias/química
Proteínas de Bactérias/genética
Hialuronoglucosaminidase/química
Hialuronoglucosaminidase/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies); 0 (Bacterial Proteins); 0 (Peptide Library); 0 (Polymers); 0 (polyol); EC 3.2.1.35 (Hyaluronoglucosaminidase)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170807
[Lr] Data última revisão:
170807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170422
[St] Status:MEDLINE



página 1 de 548 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde